Prevalence and treatment of hyperlipidemia in patients with chronic hepatitis C infection

Murthy, G Divakara; Vu, Khoa; Venugopal, Sushma

doi:10.1097/meg.0b013e32831b4698

Cited by 9 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main function of lipoproteins is transporting lipids throughout the body. Our report also showed hyperlipidaemia was associated with anti‐HCV seropositivity in persons with severe haemophilia, which was consistent with previous studies indicating a high prevalence (70%) of hyperlipidaemia in general population infected with HCV 9 …”

Section: Total Number (N = 245) Era a < 1990 Era B 1990 ‐ 2000 Era C ≧ 2000 P Value N = 122 % N = 61 % N = 62 %supporting

confidence: 93%

“…Our report also showed hyperlipidaemia was associated with anti-HCV seropositivity in persons with severe haemophilia, which was consistent with previous studies indicating a high prevalence (70%) of hyperlipidaemia in general population infected with HCV. 9 Current therapeutic approaches have prolonged the life expectancies of PWH. Consequently, age-related comorbidities are an emerging issue as the population of elder continues to rise, resulting in an increased demand for comprehensive haemophilia care.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Transfusion‐transmitted infection and comorbidities in patients with severe haemophilia: A longitudinal birth cohort analysis

et al. 2020

View full text Add to dashboard Cite

Haemophilia A (HA) and haemophilia B (HB) caused by mutations in the genes encoding clotting factor VIII and factor IX, respectively, are the most common inherited bleeding disorders. 1 The mainstay of treatment for HA and HB is replacement of the missing clotting factors. However, a serious potential complication that has been recognized in affected patients is transfusion-transmitted infection (TTI), which includes hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) 2,3 Several studies have suggested that high prevalence of HCV infection persists among persons with haemophilia (PWH). 4,5 Many PWH were exposed to long-standing HCV infection in the mid-1980s and developed chronic liver disease (CLD) and hepatocellular carcinoma (HCC). 6Improvements in the safety and efficacy of replacement therapy in the past few decades had led to an increased life expectancy for PWH. Therefore, age-related comorbidities are an emerging and challenging issue in haemophilia comprehensive care. 7This study aimed to investigate the prevalence of TTIs and comorbidities in persons with severe haemophilia and to assess differences among 3 birth cohorts constructed by critical change of haemophilia therapy using a multicenter-based database in Taiwan.The study was approved by the Institutional Review Board of all participating sites in Taiwan (IRB No. CF14354A). Data obtained from the registry database of the Taiwan Society of Thrombosis and Hemostasis (TSTH) from July, 2014 to June, 2019 were analysed. All of patients with severe HA or severe HB, defined as a baseline level of clotting factor activity less than 1%, were enrolled and divided into different birth cohorts. Critical changes of haemophilia therapy in Taiwan were identified and used as landmarks to construct 3 birth cohorts. Era A included PWH born prior to 1990 when virus-inactivated plasma clotting factor concentrate (CFC) was used only in few PWH who could be covered by labour or government employee health insurance because of the lack of national health insurance (NHI) reimbursement. Almost all PWH relied on cryoprecipitates during AIDS pandemic period due to fear of HIV infection by the imported CFC. Era B included PWH born from 1990 to 2000. NHI reimbursement for CFC was implemented since 1995, and then almost all patients were allowed to use CFC. The plasma-derived CFC was mostly heat-treated, and the solvent-and detergent-treated CFC was available for only 2-3 years during the early 1990s. Unheated CFC was still used until 1985. Era C included PWH born after 2000.These eras served as a framework for investigating how changes of haemophilia therapies affected PWH within each era over time.Data for this analysis included birth date, age at diagnosis, treatment

show abstract

Section: Total Number (N = 245) Era a < 1990 Era B 1990 ‐ 2000 Era C ≧ 2000 P Value N = 122 % N = 61 % N = 62 %supporting

confidence: 93%

mentioning

confidence: 99%

Transfusion‐transmitted infection and comorbidities in patients with severe haemophilia: A longitudinal birth cohort analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[1,2] Accumulative evidence suggested that HCV infection could exist in the heart, pancreas, kidneys, ovaries, [3–5] and even in placenta. [6,7] There is a growing body of data concerning the role of HCV in extrahepatic manifestations, including cardiovascular diseases, [8,9] immunological disorders, [10] and neurodegenerative diseases. [11,12] Placenta is a crucial organ during pregnancy for intrauterine fetal growth.…”

Section: Introductionmentioning

confidence: 99%

Maternal HCV infection is associated with intrauterine fetal growth disturbance

Huang

Hang²,

Zhong

et al. 2016

Medicine

View full text Add to dashboard Cite

Since the evidence regarding the association between maternal hepatitis C virus (HCV) infection and impaired intrauterine fetal growth had not been conclusive, the aim of the present study was to evaluate the risk of maternal HCV infection in association with intrauterine fetal growth restriction (IUGR) and/or low birth weight infants (LBW). We performed an extensive literature search of PubMed, MEDLINE, and EMBASE through December 1, 2015. The odds ratios (ORs) of HCV infection and IUGR/LBW were calculated and reported with 95% confidence intervals (95% CIs). Statistical analysis was performed using RevMen 5.3 and Stata 10.0. Seven studies involving 4,185,414 participants and 5094 HCV infection cases were included. Significant associations between HCV infection and IUGR (OR = 1.53, 95% CI: 1.40–1.68, fixed effect model) as well as LBW were observed (OR = 1.97, 95% CI: 1.43–2.71, random effect model). The results still indicated consistencies after adjusting for multiple risk factors which could affect fetal growth, including maternal age, parity, maternal smoking, alcohol abuse, drugs abuse, coinfected with HBV/HIV and preeclampsia. Our findings suggested that maternal HCV infection was significantly associated with an increased risk of impaired intrauterine fetal growth. In clinical practice, a closer monitoring of intrauterine fetal growth by a series of ultrasound might be necessary for HCV-infected pregnant population.

show abstract

“…9 Previous studies also noted that progression of CHCV infection is influenced by clinical manifestations of metabolic syndrome. 10 We did this study with an aim to find out association of lipid profile and body mass index (BMI) profile among cases having CHCV infection. The results of Body Mass Index and Lipid Profile Pak Armed Forces Med J 2021; 71 (6): 1986 this study might prove useful giving us clue about monitoring and potential management of lipid profile and BMI when cases of CHCV infection are confronted.…”

Section: Introductionmentioning

confidence: 99%

Association of Body Mass Index and Lipid Profile With Chronic Hepatitis C Infection

Younas

Hanif

Ali

et al. 2021

PAFMJ

View full text Add to dashboard Cite

Objective: To find out association of lipid profile and body mass index (BMI) profile among cases having chronic hepatitis C virus (CHCV) infection. Study Design: Cross sectional study. Place and Duration of Study: Departments of Medicine and Pathology, Combined Military Hospital, Multan Pakistan, from Mar 2019 to Feb 2020. Methodology: A total of 320 cases of both genders, aged 18-60 years, having chronic hepatitis C virus infection were enrolled. After taking relevant history and physical examination, venous blood sample of each patient was taken and sent to institutional laboratory for analysis of serum total cholesterol (TC) level, serum triglyceride (TG) level, low density lipoprotein (LDL), high density lipoprotein (HDL) were analyzed. Body mass index among all the study participants was also calculated. Results: Out of a total of 320 cases, there were 152 (47.5%) male and 168 (52.5%) female. Mean age was 41.7 ± 8.1 years. Most of the cases, 97 (30.3%) were between 41-50 years of group. Dyslipidemia was noted in 144 (45%) cases. Increasing age and increasing Body mass index were found to have statistical significance with the presence of dyslipidemia (p-value <0.05). Conclusion: Increasing age and body mass index have significant association with dyslipidemia in patients with chronic hepatitis C virus infection. Lipid profile altered among different age and body mass index groups.

show abstract

Prevalence and treatment of hyperlipidemia in patients with chronic hepatitis C infection

Cited by 9 publications

References 21 publications

Transfusion‐transmitted infection and comorbidities in patients with severe haemophilia: A longitudinal birth cohort analysis

Transfusion‐transmitted infection and comorbidities in patients with severe haemophilia: A longitudinal birth cohort analysis

Maternal HCV infection is associated with intrauterine fetal growth disturbance

Association of Body Mass Index and Lipid Profile With Chronic Hepatitis C Infection

Contact Info

Product

Resources

About